Study will test testosterone gel in hypogonadal men with diabetes
Testosterone gel (AndroGel) 1% will be evaluated for its efficacy and safety as an adjunct to oral hypoglycemic therapy in men with type 2 diabetes and hypogonadism, according to its manufacturer, Solvay Pharmaceuticals, Inc.
Testosterone gel (AndroGel) 1% will be evaluated for its efficacy and safety as an adjunct to oral hypoglycemic therapy in men with type 2 diabetes and hypogonadism, according to its manufacturer, Solvay Pharmaceuticals, Inc.
The company has initiated a proof of concept trial, and patient recruitment is underway. The double-blind, parallel, randomized, placebo-controlled study will enroll 180 patients at about 55 U.S. sites. A study extension also is planned. Results will be collected and analyzed to develop a potential phase III clinical trial.
To be considered in the study, men must be between 30 and 80 years, have a diagnosis of type 2 diabetes, and have moderate control of their diabetes with oral hypoglycemic agents. Men also will be screened for low testosterone with a blood test for final study inclusion.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.
Malpractice Consult: How likely are you to face a medical malpractice lawsuit?
July 23rd 2024"Although there is a good chance that you will face allegations of medical negligence at some point in your career, it is unlikely that you will ever be found liable by a jury," writes Victoria L. Neikam, Esq.
